108 related articles for article (PubMed ID: 2526211)
21. Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.
Mihara M; Ohsugi Y
Clin Exp Immunol; 1989 Oct; 78(1):102-7. PubMed ID: 2805413
[TBL] [Abstract][Full Text] [Related]
22. Differential effect of the autoimmune Yaa and lpr genes on the acceleration of lupus-like syndrome in MRL/MpJ mice.
Merino R; Shibata T; De Kossodo S; Izui S
Eur J Immunol; 1989 Nov; 19(11):2131-7. PubMed ID: 2599002
[TBL] [Abstract][Full Text] [Related]
23. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.
Liang B; Kashgarian MJ; Sharpe AH; Mamula MJ
J Immunol; 2000 Sep; 165(6):3436-43. PubMed ID: 10975864
[TBL] [Abstract][Full Text] [Related]
24. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
Seaman WE; Wofsy D; Greenspan JS; Ledbetter JA
J Immunol; 1983 Apr; 130(4):1713-8. PubMed ID: 6187819
[TBL] [Abstract][Full Text] [Related]
25. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
[TBL] [Abstract][Full Text] [Related]
26. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
Takahashi T; Yagi T; Kakinuma S; Kurokawa A; Okada T; Takatsu K; Aizawa S; Katagiri T
J Immunol; 1997 Sep; 159(5):2532-41. PubMed ID: 9278347
[TBL] [Abstract][Full Text] [Related]
27. FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease.
Yajima K; Nakamura A; Sugahara A; Takai T
Eur J Immunol; 2003 Apr; 33(4):1020-9. PubMed ID: 12672068
[TBL] [Abstract][Full Text] [Related]
28. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice.
Matsumoto K; Watanabe N; Akikusa B; Kurasawa K; Matsumura R; Saito Y; Iwamoto I; Saito T
Arthritis Rheum; 2003 Feb; 48(2):486-94. PubMed ID: 12571859
[TBL] [Abstract][Full Text] [Related]
29. Cellular interactions for the in vitro production of anti-chromatin autoantibodies in MRL/Mp-lpr/lpr mice.
Fisher CL; Shores EW; Eisenberg RA; Cohen PL
Clin Immunol Immunopathol; 1989 Feb; 50(2):231-40. PubMed ID: 2521586
[TBL] [Abstract][Full Text] [Related]
30. Suppressor T-cell activity in MRL/Mp-lpr/lpr mice: differential effects on primary and memory antibody responses of MRL/Mp-lpr/lpr and MRL/Mp-+/+ spleen cells to thymus dependent and thymus independent antigens in vitro.
Wilson DA
Cell Immunol; 1985 Dec; 96(2):312-26. PubMed ID: 2943418
[TBL] [Abstract][Full Text] [Related]
31. Role of T cells in the pathogenesis of autoimmune lacrimal gland disease in MRL/Mp-lpr/lpr mice.
Jabs DA; Lee B; Prendergast RA
Curr Eye Res; 1997 Sep; 16(9):909-16. PubMed ID: 9288452
[TBL] [Abstract][Full Text] [Related]
32. The influence of silicone implantation on murine lupus in MRL lpr/lpr mice.
Schaefer CJ; Wooley PH
J Rheumatol; 1999 Oct; 26(10):2215-21. PubMed ID: 10529143
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice.
Hecht M; Müller M; Lohmann-Matthes ML; Emmendörffer A
J Leukoc Biol; 1995 Feb; 57(2):242-9. PubMed ID: 7852838
[TBL] [Abstract][Full Text] [Related]
34. Autoimmune kidney disease in MRL/lpr mice inhibited by OK-432; II. Effect of indomethacin.
Mihara M; Ohsugi Y
J Pharmacobiodyn; 1992 May; 15(5):255-9. PubMed ID: 1527701
[TBL] [Abstract][Full Text] [Related]
35. Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus.
Lartigue A; Colliou N; Calbo S; François A; Jacquot S; Arnoult C; Tron F; Gilbert D; Musette P
J Immunol; 2009 Nov; 183(10):6207-16. PubMed ID: 19841185
[TBL] [Abstract][Full Text] [Related]
36. C1q deficiency and autoimmunity: the effects of genetic background on disease expression.
Mitchell DA; Pickering MC; Warren J; Fossati-Jimack L; Cortes-Hernandez J; Cook HT; Botto M; Walport MJ
J Immunol; 2002 Mar; 168(5):2538-43. PubMed ID: 11859149
[TBL] [Abstract][Full Text] [Related]
37. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A
Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253
[TBL] [Abstract][Full Text] [Related]
38. An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus.
Zhang MC; Misu N; Furukawa H; Watanabe Y; Terada M; Komori H; Miyazaki T; Nose M; Ono M
Ann Rheum Dis; 2006 Apr; 65(4):495-500. PubMed ID: 16150787
[TBL] [Abstract][Full Text] [Related]
39. Treatment of autoimmune MRL/Mp-lpr/lpr mice with cholera toxin.
Fan JL; Himeno K; Tsuru S; Nomoto K
Clin Exp Immunol; 1987 Oct; 70(1):94-101. PubMed ID: 3500817
[TBL] [Abstract][Full Text] [Related]
40. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
